Evening Dave, Alys, Shero. I finally got to read the weekend thread and I don't see too many questions and speculations but I appreciate the organization, reason and sanity. 3 out of 4 ain't bad. I also have some thoughts to impart.
I think Alpha was gun-shy because of their HIV-tainted blood scandal and they were too intimidated (Japan, not FDA) to even try to develop Lym-2 & 3. I think some Lym-1 premium has been lost but the Lym-2 kicker will restore it. I think that Bonfiglio & Co. will surprise us, and Wall Street, on the upside. I'm looking for the MVP here. Let's not forget, IMO, that Techniclone would not have taken the uncharacteristically bold step of buying back Oncolym if they had not had a bird in the hand. I believe that, for the first time, Oncolym is being shopped and the price is rising. It may be the price of admission.
As to speculation about BMY, they are Big Pharma as far as cancer treatment stateside, or at least they claim it. They do a lot of licensing. Merck likes to develop in-house, Lilly likes to cherrypick the down and out...What about the foreigners - does Switzerland still have a 6% corporate tax rate? The UK, France, The Swiss, The People's Republic are putting time, effort, and money behind the science...
A true, albeit anecdotal, story from the '90's; Lon Stone in a conference room in Bethesda with FDA personnel, the subject - TNT trials. an FDA scientist, "Merck couldn't afford this." In other words TNT is HUGE, or at least the cost of developing was until fast track (and not just the latest wrinkle because it has been ongoing). What I'm trying to say is that BMY, by itself, could not license TNT but a dozen or so BMY's could. Ask Dr. Bonfiglio.
And then consider multiple licenses for the VTA's, VE, the fusion proteins and the drawing board.
And now to the 'Skins-Giants game, I think that having been a life-long Skins fan shows a lot of character!
G'night, Davis |
